Home
Trojantec is a biopharmaceutical Company focused on identifying, in-licensing and developing innovative oncology therapeutics. Trojantec is one of a few Companies in the World developing drugs that not only attack Cancer Cells, but more importantly, destroy Cancer Stem Cells. Through research and development in this novel, exciting field, we wish to achieve the next order of magnitude of efficacy against cancer.
Latest News
|
AACR ANNUAL MEETING, March 31- April 4, 2012, CHICAGO, IL. 1st April 2012:Trojantec Ltd, a privately held developer of cancer and cancer stem cells therapeutics(www.trojantec.com), announced today in Chicago, IL, that the Company has been granted a USA patent on its Notch drug, TR4. Read more... |
|
Trojantec raises funds for research and drug development in cancer and cancer stem cell therapeutics Nicosia, Cyprus, and London, UK, November 8th, 2011. Read more... |
|
AACR ANNUAL MEETING 2011 , ORLANDO , FLORIDA. 5th April 2011: Trojantec Ltd. announced today that two studies were presented at the 102nd Annual Meeting of AAACR held at Orlando, Florida, April 2-6th 2011. Read more... |
|
Trojantec raises funds for research and drug development in cancer stem cell therapeutics Nicosia, Cyprus, and London, UK, October 11, 2010 Trojantec Ltd, a privately held developer of cancer and cancer stem cells therapeutics, announced today a series of successful fundraising efforts. Read more... |